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Highlights 
 Wrist-worn wearable activity monitors are accurate in people with PD 
 Accuracy is high at self-selected speed but poor at low walking cadences 
 Intensity of walking activity increases with increasing walking cadence 
 Cadence measured on the wrist-worn monitors was only weakly related to intensity 
 
 
 
ABSTRACT 
Introduction: The purpose of this study was to determine the accuracy of the Fitbit Charge 
HRTM and Garmin vívosmart® HR in measuring steps and reflecting intensity of activity in 
people with Parkinson’s disease (PD).  
Methods: Thirty-three people with mild-moderate PD performed six, two-minute indoor walks 
at their self-selected walking pace, and at target cadences of 60, 80, 100, 120 and 140 
beats/minute. A 500m outdoor walk with terrain challenges was also performed. Step count 
was recorded by the two wrist-worn activity trackers (Fitbit Charge HRTM and Garmin 
vívosmart® HR) and compared to an accelerometer (ActivPAL3™). Intensity was recorded by 
a portable breath-by-breath gas analyser (VO2), heart rate and Borg scale. 
Results: Both commercial activity trackers had low error (<3%) and moderate to high 
consistency at self-selected pace both indoors and outdoors (ICC 0.88-0.97; p<0.05) compared 
to the ActivPAL3™. The Garmin recorded low error (<5%) and high agreement (ICCs >0.68; 
p<0.001) for all target cadences ≥80steps/minute. The Fitbit had higher error was less 
consistent for all target cadences ≥80steps/minute. Cadence measured by the Fitbit and Garmin 
weakly reflected increases in heart rate (ICCs 0.27-0.28; p<0.05), and did not reflect VO2 or 
Borg (ICCs 0.08-0.15, p>0.05). 
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Conclusion: The Garmin device was more accurate at reflecting step count across a broader 
range of walking cadences than the Fitbit, but neither strongly reflected intensity of activity. 
While not intended to replace research grade devices, these wrist-worn devices may be a 
clinically useful adjunct to exercise therapy to increase physical activity in people with PD.  
Keywords:   
Parkinson’s disease; body fixed sensor; physical activity; wearable devices; gait  
Introduction 
Physical activity is known to improve physical function and capacity and cognitive functions 
in people with PD1. Physical activity may also play a neuroprotective role, slowing the 
progression of PD and delaying the onset of secondary problems1. Despite these known 
benefits, people with PD are substantially less physically active than healthy age-matched 
controls2. Furthermore, increasing physical activity behaviours in sedentary people with PD 
has proven difficult even with extensive coaching, goal setting and feedback3. 
 
Recent trials in people with PD have demonstrated that exercise interventions can result in 
positive improvements in physical and cognitive function in the short to medium term4,5. 
Promoting longer term physical activity behaviour change has however proven more 
challenging3. Motivation and exercise self-efficacy are two identified barriers to exercise 
participation in people with PD6,7.  Consumer activity monitors provide visual feedback on the 
volume of physical activity performed and may therefore promote motivation and self-efficacy 
for exercise and physical activity. 
 
Wearable activity monitors include a number of behaviour change techniques often used to 
increase physical activity such as self-monitoring and feedback on goal attainment8. Most 
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people, including older adults are accepting of the technology and able to quickly learn to use 
activity trackers9. Furthermore, wearable activity monitors have been shown to be an effective 
adjunct to supporting behaviour change in adults over the age of 5010. These devices may prove 
useful in improving physical activity in people with PD, however their accuracy in this 
population is yet to be tested. 
  
Accuracy of wearable activity monitors can be influenced by pattern and speed of gait, and 
anatomical placement of the device 11. Waist-worn activity monitors have been shown to be 
more accurate than wrist-worn devices at counting steps at gait speeds ranging from slow to 
fast 11. The accuracy of wrist-worn devices may be further reduced in people with PD due to 
reduced arm swing often experienced during gait in this population. Indeed, in people with 
stroke and acquired brain injury, a wrist-worn activity monitor had an error rate of over 30%12. 
Despite the impact on accuracy, in older adults’ wrist-worn devices were often preferred 
possibly due the immediate feedback provided by and easily read on the digital screen9. As 
such, the accuracy of wrist-worn activity tracking devices in people with PD should be 
investigated.  
 
Physical activity guidelines recommend that all adults, including those with gait impairments, 
should participate in at least 150 minutes of moderate, or 75 minutes of vigorous intensity 
physical activity per week13. Monitoring performance relative to these guidelines requires a 
method of estimating activity intensity. Measuring cadence during ambulant activities is an 
easy way to understand and monitor intensity of activity and has been used to categorise 
physical activity as low, moderate or high intensity in healthy adults14, people with stroke15 
and people with PD16.  In people with PD, reduced gait speed and step length is often associated 
with increased cadence17. These gait impairments may increase the energy expenditure of 
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walking in people with PD compared to those without18 Estimates of cadence-based descriptors 
of activity intensity should therefore be verified in this population. 
  
The aim of this study was to determine the accuracy of commercially available wrist-worn 
activity tracking devices, the Fitbit Charge HRTM and Garmin vívosmart® HR, to measure step 
count and reflect intensity of activity in people with PD across a variety of walking speeds and 
conditions.  
 
Methods 
 
Participants 
Thirty-three community dwelling people with idiopathic PD were recruited through movement 
disorder specialists, a database of volunteers and PD support organisations. To be included in 
the study, participants had to have a diagnosis of idiopathic PD confirmed by a neurologist; the 
ability to walk for at least 2 minutes without stopping; and be willing and able to provide 
informed consent. People with conditions other than PD that affected their walking, and those 
with unstable medical conditions, were excluded. All participants provided written informed 
consent. The study was approved by the institutional ethical review board. 
 
Procedure 
Participants attended one assessment session at a university gait laboratory when their usual 
anti-parkinsonian medications were reported to be maximally effective. They were asked to 
abstain from vigorous exercise or consuming caffeine and tobacco products for 3 hours prior 
to the assessment. Characteristics including age, gender, disease duration, falls history and 
dopamine dosage was collected by interview. Disease severity was measured using the motor 
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subscale of the Unified Parkinson’s Disease Rating Scale (UPDRS-III)19 and stage of disease 
rated using Hoehn and Yahr scale (HY)20. Severity of gait freezing was measured using the 
Freezing of Gait Questionnaire (FOG-Q)21. To characterise gait capacity, comfortable and fast 
gait speed were measured while participants walked 10m over a 7m instrumented GAITrite 
mat (CIR Systems Inc, NJ, USA) positioned in the middle of the path. Current levels of physical 
activity were captured using the National Aeronautics and Space Administration/Johnson 
Space Centre physical activity status scale (NASA)22. Participants wore a Fitbit and Garmin 
device on each wrist, and an ActivPAL3™ on the right anterior mid-thigh.  
 
Participants completed six two-minute walks on an indoor, uncluttered 44m circuit. The first 
walk was performed at their self-selected walking pace. For the following five walks, 
participants were asked to walk in time with a metronome set at 60, 80, 100, 120 and 
140 steps per minute. These cadences were selected as they are currently used in definitions of 
walking intensity to measure free-living ambulatory activity in healthy adults14, people with 
PD16 and after stroke15. The order of walks was randomised, and each participant was given a 
30 second familiarisation period. After each walk participants rested in sitting for at least 2 
minutes or until their heart rate returned to its resting level. Participants then completed a 500m 
outdoor walking circuit. The route incorporated both terrain challenges (slopes, grass and 
stairs) and crowds to reflect challenges commonly identified by people with PD when walking 
in the community23. 
 
Instruments and measures 
The Fitbit Charge HRTM (Fitbit Inc, San Francisco, California, USA) and Garmin vívosmart® 
HR (Garmin International, Olathe, USA) are small, wearable activity trackers that are worn 
like a watch. Each participant wore four devices: one of each type on each wrist, with the one 
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placed most distally randomised between individuals. Step count was recorded from both 
devices at the beginning and end of each walking trial and the difference was calculated to 
determine the number of steps taken. An ActivPAL3™ (PAL Technologies Ltd., Glasgow, UK) 
was affixed to the anterior middle right thigh with hypoallergenic tape. It is a 15g triaxial 
accelerometer which records at a frequency of 20Hz and provides measures at 15 second 
epochs. It has established accuracy for measuring step count in older adults with and without 
impaired motor function24, and has been used widely in people with PD2,16. Step count and 
cadence (steps/minute) were calculated for each trial. 
 
Intensity of activity was measured via three methods. Oxygen consumption (VO2) during each 
walking test was measured using a portable breath-by-breath gas analyser, the Metamax 
(CORTEX, Leipzig, Germany). Heart rate was measured via a calibrated chest worn heart rate 
monitor affixed (Polar Ltd., Australia). Perceived exertion was rated out of 20 by participants 
at the beginning and end of each circuit using the Borg Scale25. 
 
Data analysis 
Data were screened for normality via Shapiro-Wilk and extreme outliers removed. Descriptive 
statistics were used to summarise participant characteristics. Activity tracker data was 
separated into most or least affected side, as determined by the individual’s combined score on 
the rigidity and bradykinesia items from the motor subsection of the UPDRS. To compare the 
accuracy of the devices with the ActivPAL3™, the mean difference, absolute percentage error 
(APE) and limits of agreement (LOA) were calculated (see formula below) and paired t-tests 
performed. Bland –Altman LOA plots were created26.  
 
APE= |mean difference (device- ActivPAL3™)|  X 100 
AC
CE
PT
ED
 M
AN
US
CR
IPT
|mean (device, ActivPAL3™)| 
 
LOA= mean difference ± (1.96 X standard deviation of the mean difference) 
 
The strength of association between the outputs from each of the devices was compared to the 
ActivPAL3™ using Intra-class Correlation Coefficients (ICC3,1). Repeated-measures ANOVA 
were used to determine differences between devices and to determine differences in measures 
of activity intensity (oxygen consumption, perceived exertion and heart rate) across the 
different speeds and conditions (60, 80, 100, 120, 140 steps per minute). ICCs were performed 
to determine the strength of the relationship between measures of activity intensity (oxygen 
consumption, perceived exertion and heart rate) and cadence. Data was analysed using SPSS 
22.0 (IBM. Chicago, Illinois, USA) and significance level was P<0.05. 
 
Results 
A total of 33 people (64% male) with mild to moderate PD (94% HY stage 1 or 2), a mean(SD) 
age of 69(8) years, and disease duration of 6(6) years participated (Table 1). There was no 
significant difference between the number of steps counted on the most and least affected sides 
(p > 0.078) therefore, only data from the devices worn on the most affected side were included 
in the analysis. 
 
When walking at a self-selected pace indoors or out, both wrist-worn devices recorded with 
low error (APE <3.0%) and high consistency (ICC ≥ 0.88) compared to the ActivPAL3TM 
(Table 2). Both devices recorded with greater consistency during the outdoor walk (ICC = 0.94 
- 0.97) compared to the indoor walk (ICC = 0.88 – 0.93). Compared to the ActivPAL3TM, both 
wrist-worn devices showed high error levels (APE 37-60%) and poor consistency (ICC = 0.36) 
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at the lowest cadence (60 steps/min), tending to underestimate step counts.  For cadences of 80 
and above, the Garmin device demonstrated low error (APEs < 5.0%). At these cadences, the 
step count recorded by the Garmin device, was also strongly associated with the ActivPAL3TM 
(ICC: 0.68 – 0.89, p < 0.05). The Fitbit device counted steps with greater error (APE 3.5 -
17.6%) and poorer consistency (ICCs: 0.17 – 0.42; p > 0.065) for each of the cadences between 
80 and 140 steps/minute.  
 
There was a main effect of cadence for oxygen consumption (p < 0.001), heart rate (p < 0.001) 
and perceived exertion (p <0.037) (Table 3). There was a significant increase in oxygen 
consumption, heart rate and perceived exertion for each increase in cadence from 60 to 140 
steps/minute, suggesting that altering cadence was an appropriate means to change intensity of 
activity. Fitbit Charge HRTM and Garmin vivofit® HR step counts were weakly associated with 
increases in heart rate across cadences of 60-140 steps/min (ICCs 0.27-0.28; p<0.05), and did 
not reflect changes in oxygen consumption or perceived exertion (ICCs 0.08-0.15, p>0.05) 
(Table 4). 
 
Discussion 
This study aimed to determine whether two wrist-worn activity trackers, the Garmin 
vívosmart® HR and Fitbit Charge HRTM could accurately determine step count and reflect 
activity intensity in people with PD while walking at difference cadences, indoors and out. 
Contrary to our hypothesis, we found that both devices provided valid measures of step count 
during indoor and outdoor walking at a self-selected pace, however, both activity trackers were 
less accurate at low cadence. Step count recorded by the Garmin vívosmart® HR was highly 
consistent with the ActivPAL3™ across cadences of 80-140 step/min but the Fitbit Charge 
HRTM was less accurate at these walking paces. Overall, the Garmin vívosmart® HR may offer 
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a more valid measure of steps in people with Parkinson’s disease. Step count measures from 
both devices were not reflective intensity of activity.  
 
To be useful to monitor free-living activity, devices need to accurately record activity with a 
variety of environmental challenges. In the current study, both devices demonstrated low error 
when walking at a self-selected speed whether indoors or out. Greater accuracy was found in 
the outdoor walking condition, where terrain and environmental challenges were encountered. 
These findings suggest that either monitor may be beneficial for recording continuous outdoor 
walking activity. Further research is however required to confirm the accuracy of wrist-worn 
devices in "free-living" conditions where there are likely to be periods of slower walking, 
shorter and longer walking distances and periods of upper limb use that may influence device 
accuracy27.  
 
The reduced accuracy of the devices at the lowest cadence supports previous research of wrist 
and waist-worn devices that show greater error at slower speeds11. Inaccuracy may be related 
to changes in gait pattern and strategies used to maintain pace and balance when walking at a 
slower or faster pace than usual. Arm swing is often reduced in people with PD, and this is 
likely to be further reduced at slow gait speeds, potentially contributing to the underestimation 
of steps at a lower cadence in people with PD. Whether this degree of reduced arm movement 
often observed in people living with stroke or more advanced PD adversely affects accuracy 
the accuracy of wrist-worn activity monitors remains to be investigated.  
 
Basic activity trackers such as pedometers have been shown to aid in increasing physical 
activity in various populations and may be used to promote behaviour change strategies such 
as goal setting28. With advances in technology, wearable armbands have become relatively 
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affordable and most incorporate a variety of behaviour change techniques designed to promote 
increased physical activity8. The largest study to improve physical activity in PD concluded 
that an intervention using a physical activity monitor for feedback and personalized 
motivational coaching alone was no more effective at increasing self-reported physical activity 
in sedentary people with PD than advice promoting safe movement3. Post hoc analysis of this 
data however revealed that participants with greater levels of physical fitness and better 
walking ability demonstrated greater increases in physical activity than the control group29. 
These results suggest real-time feedback using activity monitoring may be an effective adjunct 
to interventions aiming to increase physical activity in people with PD. 
 
Results of previous studies suggest that wrist-worn activity monitors are less accurate than hip, 
waist and leg-worn devices in healthy populations and people with gait changes related to 
neurological conditions11,12. Only wrist-worn commercially available devices were 
investigated in this study as they offer the ability to monitor activity in real time, using the easy 
to read digital screen and may therefore be more suited to monitor and increase physical 
activity. It is not suggested that wrist-worn commercial devices should be considered a 
substitute for research grade activity monitoring devices that are typically hip, waist or leg 
mounted for greater step count accuracy. 
 
Neither of the wrist-worn activity trackers reflected the intensity of activity in people with PD. 
A weak association was found between step count and heart rate, and there were no associations 
with VO2 or perceived exertion. This differs from a recent study in young adults in which step-
count recorded by the Garmin Vivofit correlated with criterion measures of energy expenditure. 
This was measured across a much broader range of gait speeds (0.7m/s to 3.33m/s) that 
included running. In the current study, the perceived exertion of walking ranged from ‘very 
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light’ to ‘somewhat hard’. A broader range of exertion, particularly including higher intensity 
activity may reveal a relationship between energy expenditure and step-count in this 
population. The results of the current study suggest that in order to achieve adequate intensity 
of physical activity, people with PD may benefit from a period of supervised exercise practice, 
using reliable methods to establish exercise intensity. 
 
A strength of this study is that we investigated readily-available wrist-worn consumer devices 
and used a protocol incorporating a range of cadences and indoor and outdoor walking with 
challenges in people with PD. Our participant sample had low baseline activity levels, thus 
reflects the population in most need of increased physical activity. We did not include those 
with advanced PD. Our protocol could have been improved by completing a longer indoor 
circuit with fewer turns (>44m/lap), as this creates the potential for inconsistency in stepping 
which may have influenced accuracy in the indoor conditions. Participants were assessed when 
their anti-Parkinsonian medication was reported to be maximally effective. Our findings may 
not accurately represent people with PD during periods of sub-optimal medication who may 
experience different gait deficits such as freezing. Finally, the scope of this study was to explore 
the accuracy of commercially available wrist-worn activity monitoring devices. These devices 
were selected due in part to their growing popularity in the population in addition to the 
behavior change techniques that they include. No comparison to the accuracy of hip, waist or 
leg-worn devices was conducted. It is not suggested that commercially available wrist-worn 
devices should be considered a replacement for more rigorous research grade activity monitors. 
 
Conclusion 
Commercially available wrist-worn activity monitors are a feasible and effective solution for 
monitoring step count in people with mild-moderate PD walking at their usual pace. The 
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Garmin vívosmart® HR was more accurate at reflecting step count across a broader range of 
walking cadences than the Fitbit Charge HRTM, but neither were able to strongly reflect 
intensity of activity. While not intended to replace research grade trunk or leg-worn devices, 
the Garmin vívosmart® HR and Fitbit Charge HRTM may be useful to monitor step count for 
clinical applications in people with PD. The Garmin vívosmart® HR did however outperform 
the Fitbit Charge HRTM at lower cadences. In addition to the use of activity monitoring, people 
aiming to achieve the physical activity guidelines would likely benefit from a period of exercise 
familiarisation using more accurate methods to ensure they are exercising at a sufficiently high 
intensity.  
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Figure 1.  
 
Bland-Altman plots of the differences between Fitbit/Garmin devices and the ActivPAL3™ (y-
axis) and the mean of the two measurements (x-axis) measured as the participant walked for 
two minutes attempting to walk at 60 and 120 steps/minute. Limits of agreement and mean 
differences are demonstrated by the dotted lines. MD= Mean difference; LLOA= Lower limit 
of agreement; ULOA= Upper limit of agreement. 
 
 
 
 
Figure 1. Bland-Altman limits of agreement plots comparing steps measured by the 
ActivPAL3™ to the Fitbit and Garmin devices worn on the most affected side. 
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Table 1. Demographic and clinical characteristics (n = 33) 
Characteristic Mean (SD) 
Age (years) 68.8 (8) 
Disease duration (years) 7.3 (6.1) 
Males, n (%) 9 (36%) 
Dopamine dosage (mg) 446 (110) 
Fallers, n (%) 12 (48%) 
Comfortable gait speed (m/s) 1.2 (0.2) 
Fast gait speed (m/s) 1.7 (0.3) 
Average self-selected cadence (steps/minute) 109.2 (6.6) 
UPDRS Motor subsection score 32.2 (12.9) 
Hoehn and Yahr scale score, n (%)                      
 Stage I  11 (44%) 
 Stage II  12 (48%) 
 Stage III  2 (8%) 
Freezing of gait questionnaire (score/24) 3.3 (2.6) 
NASA physical activity (score/10) 4.7 (2.5) 
Data presented as mean (SD) or n (%). Fallers = participants who reported falling in the last 
12 months 
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Table 2. Step count measured by the Fitbit and Garmin devices compared to the ActivPAL3™ for self-selected (indoors and outdoors) and set 
cadences 
Cadence Mean 
ActivPAL 
(SD) 
Mean 
Device 
(SD) 
Mean 
difference 
(SD) 
APE 
(%) 
LLOA ULOA ICC 95% CI 
Fitbit  
Self-selected, in 
Self-selected, out 
60 
80 
100 
120 
140 
218.2 (13.5) 
685.8 (82.5) 
109.4 (22.4) 
164.6 (12.2) 
199.6 (6.2) 
232.2 (7.1) 
257.0 (16.2) 
219.0 (20.3) 
677.9 (66.7) 
109.8 (65.6) 
188.6 (43.9) 
213.4 (23.0) 
233.1 (12.1) 
255.6 (38.2) 
0.4 (11.2) 
-6.6 (25.6) 
-1.4 (61.0) 
24.1 (43.3) 
12.6 (22.7) 
0.14 (12.1) 
-1.9 (35.5) 
2.8 
1.5 
37.2 
17.6 
6.9 
3.5 
8.8 
-24.0 
-64.5 
-129.6 
-82.3 
-44.1 
-25.1 
-77.7 
24.8 
51.4 
126.7 
130.5 
69.3 
25.4 
73.9 
0.88* 
0.94* 
0.36 
0.18 
0.17 
0.37 
0.42 
0..76 to 0.94 
0.86 to 0.97 
-0.29 to 0.69 
-0.67 to 0.59 
-0.72 to 0.60 
-0.39 to 0.71 
-0.18 to 0.72 
Garmin  
Self-selected, in 
Self-selected, out 
60 
80 
100 
120 
140 
218.2 (13.5) 
687.9 (89.0) 
111.3 (20.0) 
164.5 (12.2) 
200.7 (8.8) 
232.2 (7.1) 
257.0 (16.2) 
223.0 (14.6) 
686.1 (82.1) 
71.6 (59.4) 
162.8 (14.8) 
204.4 (6.9) 
236.3 (7.9) 
254.3 (22.6) 
5.2 (7.3) 
0.3 (25.2) 
-39.7 (54.9) 
-1.6 (8.6) 
5.4 (5.8) 
4.1 (7.2) 
-2.7 (18.9) 
2.7 
1.9 
60.0 
3.6 
3.1 
2.5 
4.8 
-13.9 
-54.8 
-171.3 
-19.9 
-10.2 
-13.1 
-43.3 
24.3 
55.3 
92.0 
16.8 
20.9 
21.3 
38.0 
0.93* 
0.97* 
0.36 
0.89 
0.71* 
0.68* 
0.70* 
0.85 to 0.97 
0.93 to 0.99 
-0.30 to 0.68 
0.76 to 0.95 
0.40 to 0.86 
0.39 to 0.85 
0.40 to 0.85 
APE= Absolute percentage error; LLOA= Lower limit of agreement; ULOA= Upper limit of agreement; ICC = Intraclass Correlation Co-
efficient; 95% CI = 95% Confidence interval. * p < 0.05.  
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Table 3. Mean (SD) of intensity measures across cadences of 60-140 steps/min 
*Heart rate based on n = 31 due to two missing values.  
 
 
 
  
 60 80 100 120 140 p-value 
Intensity Measure       
VO2 (ml.kg/min)  7.1 (1.7) 7.9 (1.6) 9.0 (2) 10.8 (2.3) 12.0 (3) <0.001 
Perceived exertion (Borg score/20)  8.8 (2.3) 9.5 (1.8) 10.1 (2.1) 10.8 (2.4) 12.2 (2) <0.037 
Heart rate (beats/min) * 82.8 (11.1) 84.8 (11.1) 87.5 (11.8) 92.8 (13.2) 96.7 (15) <0.001 
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Table 4. Association between cadence (60-140 steps/min) when measured by each device and 
measures of intensity of physical activity  
 
* p < 0.05 
 
 
 
 
  ICC (95% CI)  
Intensity Measure ActivPAL Fitbit Garmin 
VO2 (ml/kg/min)  0.23 (-.05 to .44)* 0.12 (-0.19 to 0.35) 0.15 (-0.16 to 0.37) 
Perceived exertion (Borg score/20) 0.16 (-.15 to .38) 0.08 (-0.25 to 0.32) 0.1 (-0.23 to 0.34) 
Heart rate (beats/min) 0.47 (.27 to .61)* 0.27 (-0.002 to 0.46)* 0.28 (0.01 to 0.47)* 
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